In a letter to the editor of the American Heart Associaton's Circulation magazine, researchers from Nanobac Oy, a research group in Kuopio, Finland and subsidiary of Nanobac Pharmaceuticals, Inc., announced that their findings show an association between nanobacterial infection, dental plaque and periodontal disease.
Nanobac OY scientists, Neva Ciftcioglu, Ph.D. and E. Olavi Kajander, M.D., Ph.D., with David S. McKay, Ph.D. at NASA Johnson Space Center, Houston, Texas, described their findings in a letter in the August 26, 2003 issue. Their letter was in response to a study by Harvard public health epidemiologists, Hung, Willet, Merchant, et al published in an earlier issue of the magazine. The Harvard Study showed a relationship between periodontal disease and the development of peripheral arterial vascular disease. In response, the Harvard epidemiologists agreed that the association of nanobacterial infections, dental plaque, periodontal disease and peripheral arterial vascular disease is worthy of further study.
Nanobacteria, through infection of human tissues, have the unique ability to cause both calcification deposits and inflammation inside infected tissues. They have been shown in multiple, previously published studies to be present in dental plaque, periodontal plaque, coronary artery plaque, aortic plaque, kidney stones, gallstones and in other tissues.
Nanobac Pharmaceuticals, Inc. is the leader in nanobacterial infectious disease research and development, and owns the proprietary methods of detection and treatment of nanobacterial infections. The company's nanobacterial diagnostics and prescription nanobiotic(R) medications, demonstrated to safely and effectively treat nanobacterial infections in coronary artery heart disease and vascular disease, are available to qualified physicians.
Reprints of the article, "Association between Nanobacteria and Periodontal Disease", Circulation, Volume 108, No 8, August 26, 2003, e58-e59, may be obtained online from the American Heart Association at www.circulation.com.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Fla. For more information, please visit www.nanobaclabs.com.
